Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Siltuximab for the Treatment of Cytokine Release Syndrome and Neurological Toxicity Related to Chimeric Antigen Receptor T-cell Therapy in Hematological Malignancies

Trial Status: active

This phase II trial tests the safety and effectiveness of siltuximab in treating cytokine release syndrome (CRS) and neurological side effects (toxicities) associated with chimeric antigen receptor T-cell therapy (CAR-T) in patients with blood cancers (hematological malignancies). Siltuximab may help prevent or lessen CRS and neurological toxicity caused by CAR-T.